OTTAWA, Nov. 23, 2012 /CNW/ - Biovest Corp. I ("Biovest") (BVC.P-TSX Venture Exchange), a Capital Pool Company, is pleased to provide this update to its press release dated June 13, 2012 wherein it was announced that Biovest had entered into a letter of intent with Magor Communications Corp. ("Magor"), a private technology company. Biovest and Magor continue to work towards the completion of a business combination (the "Transaction") whereby all of the issued and outstanding securities of Magor will be exchanged for securities of Biovest. In furtherance of the Transaction, on November 7, 2012, Biovest, Magor and Biovest Sub Corp. (as defined below) entered into a formal Merger Agreement (as defined below) pursuant to which the Transaction will be completed. The Transaction is intended to constitute the Qualifying Transaction of Biovest as such term is defined in Policy 2.4 of the Corporate Finance Manual of the TSX Venture Exchange (the "Exchange").
Magor was incorporated under Canada Business Corporations Act on June 8, 2007, and maintains its registered head office at 350 Terry Fox Drive, Suite 300, Ottawa, Ontario, Canada, K2K 2W5.
Magor was founded by Sir Terence Matthews ("Mr. Matthews") in 2007 in Ottawa, Ontario to develop a software-based technology solution to provide a low cost video collaboration product. Magor's visual collaboration solution seeks to capitalize on what management has identified as a significant shift in the videoconferencing market, driven in part by increasingly powerful communication hardware and the reduced cost of such hardware combined with a new system architecture which is software based. Initial sales of the Magor visual collaboration solution commenced in 2009.
The Magor visual collaboration system is a software based solution that operates on off-the-shelf hardware, using a system architecture that does not require a multipoint control unit ("MCU"), and utilizes scalable video coding. These characteristics, when combined, result in a visual collaboration solution at significantly less costs than the traditional videoconferencing solutions, which have typically used proprietary hardware and software with an architecture that requires a multipoint control unit.
Magor's MCU-less architecture and scalable video coding is a software solution that Magor's management believes will challenge the traditional videoconferencing market. Magor is also working with telecommunication companies towards the development of a cloud based video collaboration solution, which it anticipates will be commercially launched during calendar Q1 2013. In addition, Magor is developing visual collaboration software that will enable it to operate over other operating systems such as Windows, Apple OSX, Apple OS and Android, which will allow the Magor solution to be incorporated into third party device manufacturer's products. Management is in discussions with potential partners and anticipates being in a position to license this solution to such partners during calendar Q2 2013.
Magor is now working on commercializing its visual collaboration solutions. Magor generated sales (unaudited) of $394,194 in the first quarter of its 2013 fiscal year and annual sales (audited) of $474,928, $1,919,473 and $1,882,772 in 2010, 2011 and 2012 respectively. Magor's total assets for the fiscal years ended April 30, 2010, 2011 and 2012 (audited) were $3,931,580, $1,605,744 and $1,149,442 respectively, and Magor's long-term liabilities (audited) for the same fiscal years were $6,169,431, $3,470,034 and $4,651,901 respectively.
To date, Magor has raised approximately $22.2 million in order to fund the company through the development phase.
Following the announcement of the proposed Transaction on June 12, 2012, Magor completed a secured convertible debenture financing issuing $ 3,041,850 in new secured convertible debentures (the "Secured Debentures"). The financing closed in four separate tranches on July 17, 2012, August 10, 2012, September 6, 2012 and October 22, 2012. The Secured Debentures are convertible into common shares in the capital of Magor ("Magor Shares") at a conversion price of $0.59 per Magor Share. The following officers and directors of the Corporation and Magor participated in the Secured Debenture financing, purchasing in the aggregate approximately $958,130 in Secured Debentures: Dr. Calvin Stiller, Brian Baker, Michael Mueller, Garrett Herman, Mr. Matthews, John MacDonald and John Watts. In accordance with their terms, immediately prior to the completion of the Transaction, the Secured Debentures will automatically convert into Magor Shares. Upon conversion, along with each Magor Share, each debentureholder shall be issued one-half of one (0.5) warrant for the purchase of Magor Shares ("Magor Warrant"), with each whole Magor Warrant entitling the holder thereof to purchase one (1) Magor Share at an exercise price of $0.59 per share. The Magor Shares and Magor Warrants will be exchanged for equivalent securities in Biovest upon completion of the Transaction.
In addition, on October 12, 2012, Magor completed a bridge financing in the aggregate amount of $300,000 with each of Mr. Matthews (Chairman of Magor), Dr. Calvin Stiller and Michael Mueller (the "Lenders"). Each Lender was issued a secured promissory demand note with a principal amount of $100,000 (the "Notes"). The Notes mature on the earlier of a demand for repayment and April 30, 2013 and bear an interest rate of 12% per annum. Interest shall accrue on the basis of the actual number of days elapsed in a three hundred and sixty-five (365) day year, compounded monthly. In the event that the Note has not been repaid by January 11, 2013, Magor shall pay each Lender an additional fee equal to three percent (3%) of the principal amount outstanding as at such date. Furthermore, in the event that the Notes remain unpaid by April 11, 2013, Magor shall pay each Lender an additional interest payment equal to three percent (3%) of principal amount outstanding as at April 11, 2013. The Notes have been secured by a general security agreement covering all of the assets of Magor.
Magor's outstanding capitalization as of November 23, 2012 consists of: (i) 18,094,418 Magor Shares (ii) 7,115,391 convertible debenture warrants; (iii) 2,836,850 common share purchase options; (iv) $3,041,850 Secured Debentures; and (v) $4,669,297 convertible debentures ("Convertible Debentures"). Wesley Clover International Corporation ("WCIC") currently owns 46.4% of the outstanding common shares of Magor and is beneficially controlled by Mr. Matthews. In accordance with the letter of intent among the Corporation, Magor and WCIC dated June 12, 2012, all securities in the capital of Magor currently held by or hereafter acquired by WCIC are subject to a lock-up agreement between the Corporation, Magor and WCIC until such time as the Transaction is completed. Upon completion of the Transaction, Mr. Matthew's will become a director and Chairman of Biovest.
As a condition precedent to the completion of the Transaction, immediately prior to the closing of the Transaction, Magor shall have completed the following capital restructuring transactions (the "Pre-Closing Transactions"):
- Pursuant to certain debenture amending agreements having been executed by substantially all of the holders of outstanding Convertible Debentures, substantially all outstanding Convertible Debentures, including all outstanding principal and accrued interest thereon, shall be converted into Magor Shares immediately prior to the completion of the Transaction at a conversion price $1.00 per Magor Share. As a result of the debenture amending agreements, immediately prior to the closing of the Transaction approximately $4,669,297 in Convertible Debentures, plus accrued interest at a rate of 10% per annum up to an including the date of the transaction, shall be converted into Magor Shares resulting in the issuance of approximately 5,763,809 Magor Shares immediately prior to the completion of the Transaction.
- The debenture amending agreements also provide that the corresponding convertible debenture warrants, which warrants become effective upon conversion of the Convertible Debentures, shall, immediately prior to the completion of the Transaction, be surrendered to Magor for cancellation in exchange for class A shares in the capital of Magor ("Class A Shares") on a one for one basis. As a result, immediately prior to the completion of the Transaction approximately 2,012,644 Class A Shares shall be issued in exchange for the cancellation of the effected convertible debenture warrants.
- Pursuant to certain warrant amending agreements having been executed by substantially all of the holders of convertible debenture warrants, immediately prior to the completion of the Transaction, substantially all outstanding convertible debenture warrants shall be surrendered to Magor for cancellation in exchange for, on a one for one basis, Class A Shares. As a result, immediately prior to the completion of the Transaction approximately 4,895,419 Magor Class A Shares shall be issued in exchange for the cancellation of Magor's currently outstanding convertible debenture warrants.
- Pursuant to a conversion agreement among Magor and WCIC (the "Conversion Agreement"), WCIC has agreed that, immediately prior to the completion of the Transaction, an outstanding demand loan to Magor in the amount of $1,938,898 shall be converted into Magor Shares at a conversion price of $1.00 per Magor Share. As a result of the Conversion Agreement, immediately prior to the completion of the Transaction Magor shall issue 1,938,898 Magor Shares to WCIC.
Immediately prior to the closing of the Transaction and following the completion of the Pre-Closing Transactions, the capitalization of Magor shall consist of approximately: (i) 30,808,257 issued and outstanding Magor Shares; (ii) 6,397,780 issued and outstanding Magor Class A Shares; (iii) 2,836,350 issued and outstanding Magor Options; and (iv) 3,057,624 outstanding Magor Warrants.
The Qualifying Transaction
Subject to regulatory approval, on November 7, 2012, a wholly-owned subsidiary of Biovest ("Biovest Sub Corp."), Biovest and Magor entered into a merger agreement (the "Merger Agreement") whereby Biovest Sub Corp. will amalgamate with Magor Communications Corp. to form an amalgamated company. Pursuant to the Merger Agreement, the shareholders of Magor will transfer all the issued and outstanding Magor Shares, Magor Class A Shares, Magor Warrants and Magor Options to Biovest Sub Corp. in exchange for, on a one for one basis, Common Shares, Class A Shares, Biovest Warrants, Biovest Broker Warrants (as defined below) and Biovest Options respectively, in accordance with the terms and conditions set forth in the Merger Agreement. Presently 4,100,000 common shares in the capital Biovest are issued and outstanding. Upon completion of the Transaction, all of the tangible and intangible assets of Magor will be owned by and held in Biovest Sub Corp. (the wholly-owned operating subsidiary of Biovest). Following the completion of the Transaction Biovest will change its name from Biovest Corp. I to "Magor Corporation". The proposed change of name was previously approved by Biovest's shareholders at the corporation's October 17, 2012 annual and special meeting. It is expected that upon completion of the Qualifying Transaction the resulting issuer will be a Tier 2 Technology Issuer pursuant to the policies of the Exchange.
Biovest, a Capital Pool Company, intends for the Transaction to constitute its Qualifying Transaction under the policies of the Exchange. The proposed Qualifying Transaction constitutes an arm's length transaction, and as such, will not require approval by the shareholders of Biovest. The Transaction is conditional upon, among other things: (i) receiving all necessary regulatory and third party approvals and authorizations; (ii) completion of a minimum concurrent financing of $3,000,000.00 (iii) receipt of an independent valuation of Magor, if required by the Exchange; (iv) approval of the Transaction by each of the board of directors of Biovest and Magor; (v) approval of the amalgamation by the shareholders of Magor and Biovest Sub Corp.; (vi) confirmation of no material adverse change having occurred for either entity prior to closing; (vii) completion of a definitive agreement setting forth the terms and conditions for the closing of the Transaction; and (viii) completion of due diligence satisfactory to each party.
Biovest will apply to the Exchange for an exemption from the sponsorship requirements in connection with the Transaction. There is no assurance that such exemption will be granted. If such exemption is not granted, Biovest will be required to engage a sponsor for the Transaction.
Trading of the common shares of Biovest will not resume until all steps referenced in Policy 2.4 of the Exchange have been completed. Biovest will issue a further news release when the Exchange has received the necessary documentation and trading of the common shares of Biovest is set to resume.
The completion of the Transaction is conditional on the completion of a minimum concurrent financing of $3,000,000. Pursuant to an engagement letter dated September 18, 2012, Biovest and Magor have engaged Macquarie Private Wealth Inc. (the "Agent") on a commercially reasonable basis, to act as exclusive agent in connection with the concurrent financing to raise a minimum of $3,000,000 ("Minimum Offering") and up to a maximum of $5,000,000 ("Maximum Offering"). The Agent will be paid a fee in cash equal to 8.0% of the aggregate gross proceeds of the Offering (the "Agent's Fee"). In addition, the Agent will be granted an option ("Agent's Option") to acquire that number of securities equal to 8.0% of the total number of securities sold under the Offering, exercisable at the Offering price for a period of eighteen (18) months from the closing date of the Offering. Further disclosure about the Offering will be forthcoming once the terms have been finalized by Biovest, Magor and the Agent.
The net proceeds from the Offering, after deducting the Agent's Fee and other expenses of the Offering and the Transaction, which are projected to be $800,000 in the aggregate, are estimated to be $2,200,000 if the Minimum Offering is completed and $4,040,000 if the Maximum Offering is completed.
The Corporation intends to use the fund available from the Offering as follows:
|Proposed Use||Estimated portion of available funds (1)|
|Minimum Offering||Maximum Offering|
|Marketing and Sales||$1,240,000||$2,005,000|
|Research and Development||$250,000||$730,000|
|General and Administrative Expenses||$230,000||$825,000|
|Unallocated Working Capital||$100,000||$100,000|
Post -Closing Directors and Officers
Upon completion of the Transaction, the term of Biovest's current directors will end, the size of the board of directors will be expanded to 10 member and the following individuals will become the directors of Biovest: Mr. Matthews, Dr. Calvin Stiller, Michael Mueller, Michael Pascoe, Dan Rusheleau, Steve Spooner, John Watts, Scott Marshall, Jerry Edgerton and John MacDonald. In addition, it is anticipated that following the closing of the Transaction, Mr. Matthews will be appointed Chairman of Biovest, Michael Pascoe will appointed Chief Executive Office of Biovest and Brian Baker will be appointed Chief Financial Officer of Biovest. All members of the board and management bring tremendous experience in their respective fields.
Sir Terence Matthews
Mr. Matthews is presently director and Chairman of Magor. He is also the non-executive Chairman of a number of technology companies including Mitel Networks Corporation and Solace Systems. In 1972 Matthews co-founded his first technology company, Mitel Networks Corporation. He served as CEO and Chairman of Newbridge Networks Corporation until 2001, a company he founded in 1986. Mr. Matthews holds an honours degree in electronics from the University of Wales, and is a Fellow of the Institute of Electrical Engineers and of the Royal Academy of Engineering.
Mr. Pascoe is presently President and CEO of Magor Communications Corp. a position he has held since 2008. Previously Mr. Pascoe was CEO of Meriton Networks and led its private sale to Xtera Communications. Mr. Pascoe was also CEO and President of PairGain Technologies, which ADC acquired in 2000 for $3 billion. Prior to PairGain, Mike was a key member of the executive management team at Newbridge Networks Corporation (acquired by Alcatel in 2000 for US $7 billion) as the president of the U.S. division, as well as the EVP/GM of the North and South American business regions. Mr. Pascoe holds an electrical engineering degree from the University of Waterloo.
Mr. Baker presently serves as CFO of Biovest Corp. I and since 2008 he has been the CFO of BioQuest Innovations Inc. a company that provides drug development management advisory services and interim corporate management services to life science companies. In his capacity as CFO of BioQuest Innovations Inc. Mr. Baker acts as CFO for several early stage development companies including Annidis Corporation (trading on the Exchange). Mr. Baker is a Chartered Accountant and obtained his Bachelor of Commerce degree from Concordia University and began his career with Ernst & Young in 1978.
Dr. Calvin Stiller
Dr. Stiller is currently Chairman and CEO of Biovest Corp. I. He is also Professor Emeritus of the University of Western Ontario in the Departments of Medicine and Microbiology and Immunology. Dr. Stiller established the Multi-Organ Transplant Service in London, Ontario and served as the unit's chief until 1996. Dr. Stiller serves on the Board of Directors of Revera Inc. and Stem Cell Therapeutics (trading on the Exchange), and several public endeavours and foundations including, co-founder and director of MaRS (Medical and Related Sciences Discovery District), and of the Ontario Institute for Cancer Research (of which he is also Chair). He is immediate past Chair of Genome Canada and the Canadian Alliance for Health Innovation (Conference Board of Canada). He is also the recipient of numerous awards including the MEDEC Award (1992), the Order of Canada (1995) and the Order of Ontario (2000). Dr. Stiller received his MD from the University of Saskatchewan and has been the recipient of honorary doctorates from McMaster University, University of Saskatchewan and University of Western Ontario.
Mr. Mueller is presently a director of Biovest Corp. I. He is also a member of the board of directors of the Public Service Pension Investment Board (and Chair of its Human Resources and Compensation Committee), the Scarborough Hospital (and Chair of its Board), the Scarborough Hospital Foundation, Budco, AIM Therapeutics and Annidis Corporation. He also serves as strategic advisor to a number of Canadian and international companies. From 2003 to 2005, he was President and Chief Executive Officer of MDS Capital Corporation. Prior to that, Mr. Mueller held a series of senior positions at TD Bank Financial Group, including Senior Vice President and Country Head of its USA Division, Executive Vice President of Global Credit and Vice Chairman and head of Global Investment Banking. Mr. Mueller holds a Bachelor of Science from the University of Western Ontario, and a Master of Business Administration from York University.
Daniel Rusheleau founded Magor along with Mr. Matthews in 2007 and is presently a director of Magor. Mr. Rusheleau has more than 35 years of experience in the voice and data communications industry. In 1986, Mr. Rusheleau co-founded Newbridge Networks with Sir Terrence Matthews. He served as Newbridges' Vice President of Research and Development and General Manager of the Access Product Business Unit until 1993, and continued to serve on the company's Board of Directors until 1998. Prior to Newbridge, Mr. Rusheleau held engineering positions with GTE Automatic Electric, Bell Northern Research, Norpak and Mitel. Mr. Rusheleau holds a BASc degree in electrical engineering from the University of Waterloo.
Mr. Spooner is presently a director of Magor and a member of Magor's audit committee. Mr. Spooner is presently Chief Financial Officer for Mitel Networks Corporation, a communications solutions company. Mr. Spooner has global responsibility for Finance, Operations, Legal, Information Technology, M&A and Investor Relations. Mr. Spooner's past experience includes roles as CEO, COO and CFO of both emerging and established industry players including tenures at Digital, Wang, SHL System house, Cross Keys Systems, Stream Intelligent Networks and Wisdom Mr. Spooner is a Chartered Accountant (Ontario '82), a graduate of Carleton University (Commerce '80) and holds the ICD.D professional director designation from the Institute of Corporate Directors.
John Watts is presently a director of Magor and member of Magor's audit committee. Mr. Watts was President of General Dynamics Canada until 2009. Prior to his appointment as President, Mr. Watts held a series of progressively senior financial management positions in General Dynamics Canada and its predecessor, Computing Devices Canada. Mr. Watts served as Senior Vice President with responsibility for the general management of the company's Ottawa operations. Mr. Watts holds a CMA and ACIS designation.
Scott Marshall is presently a director of Magor. Most recently Mr. Marshall held the post of Senior Vice President of Engineering, Product Management and Business Development with Redback Networks, where he was responsible for technical and product leadership. He was formerly a group vice president of Cisco Systems with responsibility for multiple business units, including Dial Remote Access Servers and Concentrators, DSL, Cable, Wireless, Multi-service Switching, Voice over IP and Integrated Access Devices. Mr. Marshall also served as President and Chief Executive Officer of optical start-up CIBA Corporation and Executive Vice President of Research and Development of Newbridge Networks. He also held senior product management and engineering roles at Newbridge, Mitel and Nortel. Mr. Marshall holds a BASc in Electrical Engineering from the University of Waterloo.
Mr. Edgerton is presently a director of Magor. For nearly 20 years, Mr. Edgerton led the MCI/Verizon Business federal government business unit, building it from the ground up into a $3 billion enterprise that is widely regarded a leading federal government telecommunications organization. Prior to his long career in Telecommunications, Mr. Edgerton worked as an engineer and management consultant. Mr. Edgerton holds a Bachelor of Science degree in Electrical Engineering from North Carolina State University and a Masters of Business Administration, Professional Management from Pace University in New York.
Mr. MacDonald is presently a director of Magor. Mr. MacDonald retired from MTS All stream in December of 2008 where he held the position of President, Enterprise Division. He joined MTS Allstream, at the time known as AT&T Canada, in November, 2002. Mr. MacDonald has served on the boards of a number of companies, including Rogers Cable, Hummingbird, Stentor, and Leith Technology Corp. He was a member of the Federal Government's Advisory Council on Science and Technology. Previously, Mr. MacDonald chaired the National Selection Committee for the Federal Government's Smart Communities Program and served on the Federal Government's Information Highway Advisory Council. Mr. MacDonald holds a Bachelor of Science in electrical engineering from Dalhousie University and a Bachelor of Engineering from the Technical University of Nova Scotia.
Biovest and Magor are currently in the process of finalizing the formal disclosure documentation to be filed with the Exchange in connection with the Transaction and the Offering and made available publicly on SEDAR at www.sedar.com.
Completion of the transaction is subject to a number of conditions, including but not limited to, Exchange acceptance and if applicable pursuant to Exchange Requirements, majority of the minority shareholder approval. Where applicable, the transaction cannot close until the required shareholder approval is obtained. There can be no assurance that the transaction will be completed as proposed or at all.
Investors are cautioned that, except as disclosed in the preliminary prospectus prepared in connection with the transaction, any information released or received with respect to the transaction may not be accurate or complete and should not be relied upon. Trading in the securities of a capital pool company should be considered highly speculative.
The TSX Venture Exchange Inc. has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.
Neither the TSX Venture Exchange nor its Regulations Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE: Biovest Corp. I
For further information:
For further information about Biovest, please contact Dr. Calvin Stiller, Chairman and CEO, at (519) 858-1582 or by email at [email protected].
For further information about Magor, please contact Michael Pascoe, President and CEO, at (613) 686-1731 or by email at [email protected].